In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

Journal of Clinical Microbiology
M PfallerD Diekema

Abstract

Caspofungin is being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for emergence of in vitro resistance to caspofungin among invasive Candida spp. isolates is indicated. We determined the in vitro activity of caspofungin against 8,197 invasive (bloodstream or sterile-site) unique patient isolates of Candida collected from 91 medical centers worldwide from 1 January 2001 to 31 December 2004. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) M27-A2 method and used a 24-h prominent inhibition endpoint for determination of the MIC. Of 8,197 invasive Candida spp. isolates, species distribution was as follows: 54% Candida albicans, 14% C. glabrata, 14% C. parapsilosis, 11% C. tropicalis, 3% C. krusei, and 4% other Candida spp. Overall, caspofungin was very active against Candida (MIC50/MIC90, 0.03/0.25 microg/ml; 98.2% were inhibited at a MIC of < or = 0.5 microg/ml and 99.7% were inhibited at a MIC of < or = 1 microg/ml). Results by species (expressed as MIC50/MIC90 and the percentage inhibited at < or = 1 microg/ml) were as follows: C. albicans, 0.03/0.06, 99.9; C. glabrata, 0.03/0.06, 99.9; C. parapsilosis, 0...Continue Reading

References

Apr 16, 2002·Clinical Therapeutics·Elizabeth A StoneHarold L Kirschenbaum
Dec 20, 2002·The New England Journal of Medicine·Jorge Mora-DuarteUNKNOWN Caspofungin Invasive Candidiasis Study Group
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Valérie Letscher-Bru, Raoul Herbrecht
May 13, 2003·Expert Opinion on Pharmacotherapy·Melissa D Johnson, John R Perfect
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley C Deresinski, David A Stevens
Jul 29, 2003·Expert Opinion on Investigational Drugs·Nathan P Wiederhold, Russell E Lewis
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Luis Ostrosky-ZeichnerJeannette Lee
Mar 27, 2004·The Journal of Antimicrobial Chemotherapy·Nicholas A KartsonisCarole A Sable
Aug 28, 2004·Expert Opinion on Investigational Drugs·Michael A Pfaller
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Johan MaertensUNKNOWN Caspofungin Salvage Aspergillosis Study Group
Dec 8, 2004·Journal of Clinical Microbiology·Kung-Hung LiuWen-Chien Ko
Feb 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juan C SarriaAna M Vidal
Feb 18, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J NevadoA Hernández

❮ Previous
Next ❯

Citations

Sep 22, 2007·Medical Mycology·Sevtap Arikan
Oct 8, 2011·The Journal of Antimicrobial Chemotherapy·Pierre FournierHervé Pelloux
Dec 6, 2008·The Pediatric Infectious Disease Journal·Brian T Fisher, Theoklis Zaoutis
Nov 1, 2006·Current Opinion in Infectious Diseases·Graeme Forrest
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Santosh KatiyarThomas Edlind
Jun 27, 2007·Antimicrobial Agents and Chemotherapy·Analy S MeloBeth A Arthington-Skaggs
Oct 12, 2011·Antimicrobial Agents and Chemotherapy·Keunsook K LeeCarol A Munro
Mar 17, 2010·Antimicrobial Agents and Chemotherapy·Arnaldo L ColomboNicholas A Kartsonis
Apr 2, 2008·Antimicrobial Agents and Chemotherapy·John D ClearyDavid S Perlin
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·D AndesA Lepak
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
May 2, 2008·Journal of Clinical Microbiology·Marie Desnos-OllivierEric Dannaoui
Apr 11, 2008·Journal of Clinical Microbiology·Steven D Brown, Maria M Traczewski
Oct 26, 2007·Journal of Clinical Microbiology·Shawn R LockhartDaniel J Diekema
Sep 12, 2012·International Journal of Hepatology·David H Van ThielChristopher M Moore
May 19, 2011·BMC Infectious Diseases·Giulia MoraceMaria Teresa Montagna
Jan 1, 2008·Infection and Drug Resistance·Nathan P WiederholdChristopher R Frei
Mar 25, 2008·Therapeutics and Clinical Risk Management·Gregory EschenauerPeggy L Carver
Sep 10, 2008·Drugs·Maria J G T RüpingOliver A Cornely
Dec 24, 2010·Drugs·Sharon C-A ChenTania C Sorrell
Dec 14, 2011·Antonie van Leeuwenhoek·Suzanna F F RibeiroValdirene M Gomes
Sep 16, 2015·Critical Reviews in Microbiology·Jessica C Song, David A Stevens
Apr 3, 2008·Expert Review of Anti-infective Therapy·Joseph M FritzErik R Dubberke
Oct 7, 2009·Expert Review of Anti-infective Therapy·Maria Teresa FeraAngelina De Sarro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.